Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Ambry's ExomeNext; PartnersHealthCare's VariantWire


Ambry Genetics has launched ExomeNext and ExomeNext-Rapid. The new assays feature faster turnaround times, reduced pricing, and more comprehensive coverage than Ambry's previous exome offering. ExomeNext has a list price of $5,800 with an eight to 12-week turnaround time, while ExomeNext-Rapid has a list price of $15,129 with a two to five-week turnaround time.

Partners HealthCare and GeneInsight have launched VariantWire, a clinical consortium offering clinical laboratories in the US and Canada the ability to share genetic testing data. VariantWire leverages a crowdsourcing mechanism to help laboratories interpret the significance of genetic variants. Founding members include: Partners HealthCare Laboratory for Molecular Medicine, ARUP Laboratories, and Mount Sinai Genetic Testing Laboratory at Icahn School of Medicine in New York. The Mount Sinai Hospital in Toronto and the Canadian Open Genetics Registry have also joined.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.